Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209685 | 0.86 | HRH3 (0.75) | HRH3ADRA1A | |
| SCHEMBL6117792 | 0.82 | HRH3 (0.66) | HRH3ADRA1AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL4031972 | 0.82 | HRH3 (0.65) | HRH3 | |
| SCHEMBL4936546 | 0.82 | HRH3 (0.64) | HRH3ADRA1AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4032905 | 0.82 | KMT2A (0.57) | HRH3MAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL19598739 | 0.81 | HRH3 (0.54) | HRH3KDM1AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL14843953 | 0.79 | HRH3 (1.00) | HRH3 | |
| SCHEMBL3774013 | 0.79 | HRH3 (0.66) | HRH3ADRA1AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL19598748 | 0.79 | HRH3 (0.52) | HRH3KDM1AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL4290718 | 0.79 | HRH3 (0.60) | HRH3ADRA1AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | claimed |
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | claimed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | DRD2, DRD4, PNMT | HRH3 620/4885ADRA1A 558/4885KDM1A 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.